Russian drugmaker Pharmasyntez has asked the Kremlin for permission to produce a generic version of U.S. firm Gilead Sciences’s COVID-19 treatment remdesivir without а patent, the Vedomosti newspaper reported on Monday. Siberia-based Pharmasyntez previously approached Gilead requesting a voluntary licence to produce and distribute the drug in Russia, the company’s director, Vikram Punia, had told Reuters this year. Pharmasyntez did not immediately respond to a request for comment. …read more
Source:: Yahoo Finance
